392 related articles for article (PubMed ID: 25311239)
1. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
3. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
4. PDE-5 inhibitors: clinical points.
Doumas M; Lazaridis A; Katsiki N; Athyros V
Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
[TBL] [Abstract][Full Text] [Related]
5. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
[TBL] [Abstract][Full Text] [Related]
6. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
[TBL] [Abstract][Full Text] [Related]
7. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
10. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
11. Effect of levitra on sustenance of erection (EROS): an open-label, prospective, multicenter, single-arm study to investigate erection duration measured by stopwatch with flexible dose vardenafil administered for 8 weeks in subjects with erectile dysfunction.
Shin YS; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
Int J Impot Res; 2015; 27(3):95-102. PubMed ID: 25471318
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
13. Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
Sheweita SA; Wally M; Hassan M
Oxid Med Cell Longev; 2016; 2016():4970906. PubMed ID: 27800121
[TBL] [Abstract][Full Text] [Related]
14. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
[TBL] [Abstract][Full Text] [Related]
15. A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
van Landingham SW; Singman EL
Am Orthopt J; 2015; 65():109-14. PubMed ID: 26564936
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.
Bai WJ; Li HJ; Jin JJ; Xu WP; Sebastian S; Wang XF
Asian J Androl; 2017; 19(4):500-504. PubMed ID: 27101805
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Sildenafil in Men With Sexual Dysfunction and Spinal Cord Injury.
Ohl DA; Carlsson M; Stecher VJ; Rippon GA
Sex Med Rev; 2017 Oct; 5(4):521-528. PubMed ID: 28341580
[TBL] [Abstract][Full Text] [Related]
18. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
19. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
20. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
Mostafa T; Alghobary MF
Sex Med Rev; 2022 Jul; 10(3):392-402. PubMed ID: 34903486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
